I've got a very weak signal
http://www.assisearch.it/broker/ zetia cost Long after safety questions were raised, though, Roche was still highlighting aleglitazar as a solid blockbuster hopeful in the late-stage pipeline. Now Roche can add another high-profile failure after setting up a study with 7,000 patients, despite the odds that they were exposing patients to serious side effects.